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Temperature-Sensitive Nanocapsules for Controlled Drug Release Caused
by Magnetically Triggered Structural Disruption
Abstract
Self-assembled nanocapsules containing a hydrophilic core and a crosslinked yet thermosensitive shell have
been successfully prepared using poly(ethylene-oxide)-poly(propylene-oxide)-poly(ethylene-oxide) block
copolymers, 4-nitrophenyl chloroformate, gelatin, and 1-ethyl-3-(3- dimethylaminopropyl) carbodiimide.
The core is further rendered magnetic by incorporating iron oxide nanoparticles via internal precipitation to
enable externally controlled actuation under magnetic induction. The spherical nanocapsules exhibit a
hydrophilic-to-hydrophobic transition at a characteristic but tunable temperature reaching 40ºC, triggering a
size contraction and shrinkage of the core. The core content experiences very little leakage at 25ºC, has a half
life about 5 h at 45ºC, but bursts out within a few minutes under magnetic heating due to iron oxide
coarsening and core/shell disruption. Such burst-like response may be utilized for controlled drug release as
illustrated here using a model drug Vitamin B12.
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Nanocapsules containing magnetic iron
oxide (brown precipitates) and a model
drug (vitamin B12) encapsulated inside a
cross-linked two-layered thermosensitive
PEO-PPO-PEO shell abruptly shrink above
the transition temperature (40.5 8C),
which dramatically increases the drug
release (compare two lower curves); they
also release the drug in a burst upon
remote magnetic heating (upper curve).
Temperature-Sensitive Nanocapsules for Controlled
Drug Release Caused by Magnetically Triggered
Structural Disruption
By Ting-Yu Liu, Kun-Ho Liu, Dean-Mo Liu, San-Yuan Chen, and I-Wei Chen*
1. Introduction
Thermally sensitive drug delivery carriers that can be remotely
actuated are attractive for therapeutic and patient management.
One possible approach is to use a composite carrier made of a
magnetic core inside a thermally sensitive polymer micelle with a
temperature-dependent drug release profile, so that when the
core is self-heated in response to an external magnetic stimulus it
triggers the release of the drug contained within the micelle. The
idea is a natural extension of two concepts, (i) magnetic heating
that has been used for tumor treatment (i.e., hyperthermia) and (ii)
thermally induced volume/hydrophobicity transition that has been
observed in certain polymers and hydrogels. However, composite
magnetic nanoparticles that combine attributes of acceptable bio-
compatibility, fast actuation, high on/off ratio of drug release and
an operation temperature at about the physiological temperature
will require a careful design of material
constituents and their self-assembly. Here
we undertake such a study using poly
(ethylene-oxide)-poly(propylene-oxide)-poly
(ethylene-oxide) (PEO-PPO-PEO) copoly-
mers and iron oxide nanoparticles as
building blocks for the magnetic nanopar-
ticle and vitamin B12 as a model drug;
crosslinking agents were also introduced to
modify the composite nanostructure.
As background, the idea of using
external magnetic fields to achieve drug
release from polymer composites was first
reported by Kost et al. who demonstrated
insulin release from a magnetic composite
of ethylene vinyl acetate under a low
frequency magnetic field.[1–2] Recently,
De Paoli et al.[3] reported magnetically
enhanced dextran release (which simulates
protein release) from a magnetic nanocomposite made of a
collagen gel. Magnetic biocompatible iron oxide nanoparticles
were used in the latter study as in our previous work on
ferrogels,[4] but they both involved bulk gels instead of colloids.
Colloids of iron oxide nanoparticles can be used as a delivery
vehicle: for example, a single-strand DNA can be grafted to the
nanoparticle; a dye-labeled complement can then be reversibly
associated to or dissociated from it depending on the tempera-
ture.[5] On thermally sensitive polymers, Choi et al.[6] reported
pluronic/heparin nanocapsules that exhibited a reversible (1000)
volume transition when cycled between 25 and 37 8C. Their study
built on the well-known properties of PEO-PPO-PEO triblock
polymers (biocompatible and commercially known as pluronic)
that manifest a range of critical micellization temperature (CMT)
for volume/hydrophobicity transition, but it further enhanced the
volume change by crosslinking the outer shell. To aim at an
unprecedentedly fast drug release under a remote magnetic
trigger, we have combined these considerations in our design
which contains (i) a collapsible magnetic core of iron oxide
immersed in a water solution of vitamin B12, (ii) a fast-breathing
nanosized two-layer shell of thermally responsive PEO-PPO-PEO
polymer, and (iii) a crosslinked outer shell that stabilizes the
nanoshell while maintaining the CMT, the volume change and the
drug release. The preparation procedure following the self-
assembly schemes of Figure 1a and b, the experimental evidence
(from transmission electronmicroscopy, dynamic light scattering)
in support of the Schemes, and the thermal responses and drug
release characteristics of the nanoparticles are described below.
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Self-assembled nanocapsules containing a hydrophilic core and a crosslinked
yet thermosensitive shell have been successfully prepared using
poly(ethylene-oxide)-poly(propylene-oxide)-poly(ethylene-oxide) block
copolymers, 4-nitrophenyl chloroformate, gelatin, and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide. The core is further rendered magnetic by
incorporating iron oxide nanoparticles via internal precipitation to enable
externally controlled actuation under magnetic induction. The spherical
nanocapsules exhibit a hydrophilic-to-hydrophobic transition at a
characteristic but tunable temperature reaching 40 8C, triggering a size
contraction and shrinkage of the core. The core content experiences very little
leakage at 25 8C, has a half life about 5 h at 45 8C, but bursts out within a few
minutes under magnetic heating due to iron oxide coarsening and core/shell
disruption. Such burst-like response may be utilized for controlled drug
release as illustrated here using a model drug Vitamin B12.
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2. Results
2.1. Structure of NPC-Activated F127 and F68
1HNMR spectra are shown in the Supporting Information Figure
S1&Q1Please check the changemade here in the text.& for F127-
NPC and F68-NPC in deuterated chloroform
(CDCl3) solution. The activated polymer
differs from the unactivated one in that the
terminal alcohols on PEO-PPO-PEO are con-
verted into nitrophenyl groups in a chlorafor-
mate environment. This is supported by the
spectra which give evidence of protons in the
ortho (o)-position (near the –NO2 side) in
the nitrophenyl (NO2Ph) group, protons in the
meta (m)-position (near the –COO side) in the
nitrophenyl group, and signals associated with
–NO2Ph–OCOO–CH2 which identifies NPC’s
attachment to the –OH group of PEO. Other
structures indicate a PEO-PPO-PEO backbone
including the PEO–CH2–units and the
PPO–CH3 units.
2.2. Size of Nanocapsules
Double-layer F127-NPC and F68-NPC nano-
capsules of different sizes at 25 8C are shown
in Figure 2. They are F127-NPC-DE in
Figure 2a and F68-NPC-DE in Figure 2b, both
in the form of double-emulsion (W1-in-oil-in-
W2), to be compared with single-emulsion (oil-
in-W2) nanocapsules (F127-NPC-SE and F68-
NPC-SE) and W1-in-oil inverse micelles (F127-
NPC-W1-in-oil and F68-NPC-W1-in-oil in the
insets). For both polymers, the size of the
nanocapsules decreases with increasing con-
tent of the polymer, but the size is always
smaller for the F127-series than for the F68-
series. Regardless of the polymer used, the
resulting nanocapsules normally show a size
decrease in the order of DE> SE>W1-in-oil.
Moreover, in the case of the DE and SE series, a
constant size is reached when the polymer
concentration is around 1.0 g mL1. This
critical concentration for maintaining a con-
stant size was employed in all subsequent
experiments.
2.3. Size Variation of the Crosslinked
Nanocapsules
The size distributions of double-layer nano-
capsules F127-NPC-DE before and after
gelatin-cross-linking are shown in Figure 3.
With the addition of 1mg mL1 gelatin in the
W2 phosphate buffered solution (PBS) solu-
tion, the size increases slightly from a peak value of 28.4–35.6 nm.
This increment is mostly caused by a small increase in the CMT
(from 21.9 to 22.8 8C, see Table 1) due to the presence of gelatin;
this point will be supported by other CMTdata to be detailed later.
A high concentration of gelatin, e.g., 5 and 10mg ml1, broadens
the size distribution considerably and causes a secondary peak at
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Figure 1. a) Chemical reactions, self-assembly and schematic structures of various nanocap-
sules, b) procedure for encapsulating drug and iron oxide into nanocapsules and events triggered
by magnetic heating: volume shrinkage, core collapse, heat conduction, and drug release.
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a very large size (Fig. 3, inset), indicating agglomeration has
occurred possibly by forming cross-linking bridges between
nanocapsules. Accordingly, an optimal concentration of 1mg
ml1 gelatin was selected in the W2 PBS solution for further
study.
Likewise, the size of nanocapsules after the second cross-
linking using EDCwasmeasured where a size decrease from 35.6
to 30.5 nm was found as shown in Table 1 (dRT). A similar trend
was found for F68 nanocapsules (Table 1). Since the change in
CMTdue to EDC, from 22.8 to 22.4 8C (Table 1) is relatively small,
the size shrinkage may be attributed to a more compact structure
after –NH2 and –COOH cross-linking.
A freshly formed F68-NPC-DE nanocapsule after double
emulsion has a spherical geometry as shown in the TEM image in
Figure 4a. After washing five times and dialysis, the nanocapsule
(Fig. 4b) is about 100 nm, which is very close to the DLS peak
value (see Table 1). After gelatin and EDC cross-linking there is
little further change in size but a higher electron density has
developed on the particle skin (Fig. 4c).
2.4. Precipitation and Encapsulation of Iron oxide
Evidence for the formation of iron oxide (IO) nanocrystals inside
the nanocapsules is shown in Figure 5 for F68-NPC-DE after
gelatin and EDC crosslinking. The size is again about 100 nm
www.afm-journal.de
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Figure 2. Diameter of nanocapsules measured by DLS of a) F127 and
b) F68 series. DE is a water-in-oil-in-water structure, SE is an oil-in-water
structure, and the inset is a water-in-oil structure.
Figure 3. Diameter distribution of F127-NPC nanocapsules after cross-
linking by different amount of gelatins. Inset: same with a more extended
size range.
Table 1. Characteristics of F127 and F68-series nanocapsules at 1 g mL1 pluronic.
Samples Non-activated NPC-activated Gel-modified EDC-modified Iron oxide
F127 F68 F127-NPC F68-NPC F127-Ge F68-Ge F127-EDC F68-EDC F68-IO
CMT [8C] 25.8 43.2 21.9 39.3 22.8 40.1 22.4 39.6 40.5
Size and size ratio
dmax [nm][a] 115.7 143.1 78.2 86.4 91.4 105.3 82.1 97.0 113.1
dRT [nm][b] 60.8 135.2 28.4 85.3 35.6 101.5 30.5 94.2 108.3
dmin [nm][c] 23.6 22.1 27.3 22.0 27.3 23.8 25.1 23.6 43.1
dmax/dmin 4.9 6.5 – – 3.3 4.4 3.2 4.1 2.6
Drug release (ratio)
Ratio45/4[d] – 12.1 – – – 39.4 – 45.5 57.3
Ratio45/25[e] – 5.9 – – – 11.6 – 14.3 17.2
Ratio45/37[f ] – 3.5 – – – 6.8 – 8.2 9.5
[a] 10 8C for F127-series and 20 8C for F68-series. [b] Room temperature (25 8C). [c] 40 8C for F127-series and 50 8C for F68-series. [d] Ratio of cumulative
percentage release after 6 h at 45 8C, to that at 4 8C. [e] Ratio of cumulative percentage release after 6 h at 45 8C, to that at 25 8C. [f ] Ratio of cumulative
percentage release after 6 h at 45 8C, to that at 37 8C.
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(Fig. 5a) and the skin (6–8 nm) is clearly of a higher electron
density (Fig. 5b). In addition, there is evidence of chain
crystallization (periodic fringes in highlighted boxes in Fig. 5b)
in the corona of the nanocapsules. At higher magnification, the
nanocapsule shows a contrast modulation due to particles of a
size of 5–10 nm (Fig. 5c). These particles are crystalline as
evidenced by the selected area diffraction pattern in Figure 5d,
indicating the Fe3O4 crystal planes of [200], [311], [400], and [511].
2.5. Thermosensitive Behavior and CMT
Nanocapsules exhibit thermally sensitive behavior similar to that
of the PEO-PPO-PEO polymer showing shrinkage above the
CMT, signifying a hydrophilic/hydrophobic transition. The CMT
and volume change can be altered by the chemical modification
(e.g., NPC and gelatin) which provides a way for fine tuning to suit
the drug release application. This was determined by measuring
the capsule size as a function of temperature, shown in Figure 6,
where a transition is manifested by a large volume shrinkage. For
data quantification, the CMT is defined as the inflection point of
the curve, and a size ratio is defined using dmax/dmin where dmax is
www.afm-journal.de
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Figure 4. Transmission electron micrographs of F68 series nanocapsules
a) before dialysis, b) after repeated washing and dialysis, and c) after gelatin
and EDC cross-linking.
Figure 5. Transmission electron micrographs of a) fully cross-linked F68
nanocapsules containing iron oxide nanoparticles, b) a high electron
density shell of a thickness about 6–8 nm, with a corona region highlighted
to show periodic modulation presumably due to polymer chain crystal-
lization, and c) contrast modulation due to iron oxide nanoparticles.
d) Selected area electron (SAE) diffraction pattern of several single crystals
of various orientations.
Figure 6. Diameter of nanocapsules measured by DLS decreases abruptly
at about CMT. F68 series has higher CMT than F127 series.
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the maximum particle diameter below the CMT at the lowest
measurement temperature and dmin is the minimum particle
diameter above the CMT at the highest measurement tempera-
ture. It is then clear that the larger size of the F68 series is mainly
due to a much higher CMT (43.2 8C) than that of F127 (25.8 8C).
(This largely reflects a higher EO/PO ratio in F68, which is 5.24,
compared to that of F127, which is 3.08.) In addition, there is a
slight decrease (about 4 8C) of CMT for activated polymers,
presumably because NPC addition causes an increase of
hydrophobicity. In contrast, the increase (about 1 8C) in CMT
is small in gelatin-cross-linked nanocapsules, and the increase
(about 0.5 8C) when EDC was added is even smaller. These
changes of CMT summarized in Table 1 are consistent with the
size data at 25 8C.
The size ratio of the nanocapsule significantly decreases when
it is cross-linked by gelatin, but the further decrease is small when
it is additionally cross-linked by EDC (row 5 in Table 1).
Incorporating IO into F68-EDC decreases the size ratio from 4.1
(corresponding to a volume ratio of about 67) to 2.6
(corresponding to a volume ratio of 18); see row 6 in Table 1.
From Figure 6, it is clear that the IO addition causes a decrease of
dmax and an increase of dmin, so both the hydrophilic ‘‘swollen’’
state and the hydrophobic ‘‘shrunk’’ state appear to be sterically
constrained from reaching their respective fully relaxed sizes.
Since the F68 series shows a higher ratio than the F127 series, it
was selected to encapsulate B12 for drug release studies.
2.6. Drug Release with and without Magnetic Heating
Cumulative release of vitamin B12 as a function of time is shown
in Figure 7 for four F68 series double-layer nanocapsules: F68
(neat polymer), F68-Ge (gelatin cross-linked), F68-EDC (further
EDC crosslinked), and F68-IO (IO-containing and fully cross-
linked). The data were obtained at four temperatures, 4, 25, 37,
and 45 8C, and fitted with Equation (2)&Equation 1 has been
changed to Equation 2 and vice versa in order to make it in
sequence. Please check.& giving the fitting parameters listed in
Table 2. Although some data (those with n far away from 0.5) do
not warrant an interpretation based on diffusion mechanisms, to
allow a more quantitative comparison we nevertheless force-fit
the data with the following expression[7] to obtain the apparent
‘‘diffusivity’’ De listed in Table 2,
Mt
M1
¼ 4 Det
pd2
 1=2
(1)
This fitting was performed for Mt/M1< 0.6. It is then clear
that there is a systematic reduction of De in the order of
F68> F68-Ge>F68-EDCF68-EDC-IO, in addition to the
obvious increase of De with the temperature. This indicates that
vitamin B12 release is a thermally activated process, and
crosslinking of the shell slows down the release.
From a practical viewpoint, a large on/off ratio is desired. This
would require a very large ratio of the 45 8Crelease to that at either
the physiological temperature (37 8C) or the storage/application
temperature (4 8C/25 8C). These ratios are listed in Table 1 using
the cumulative release after 6 h. It is clear that crosslinking
significantly increases the ratio, and the incorporation of IO does
not cause any adverse effect. The ratio comparing 45 8C (>CMT)
and 37 8C (<CMT) is 9.5 indicating a clear effect of the transition.
Meanwhile, the slow release at 4 and 25 8C being only 1/57 and 1/
17, respectively of that at 45 8C assures a long shelf time of this
drug carrier.
Lastly, the effect of magnetic heating (with the solution held in
a water bath of 15 8C) is shown in Figure 7 (see symbols&What
symbol???&) which evidently has a much larger cumulative
release in just a few minutes: about 40% cumulative release is
reached in the first 5min, which is about 20 times the rate
www.afm-journal.de
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
1
2
3
4
5
6
7
8
9
10
11
12314
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Table 2. Summary of fitting constants (n and k) for cumulative release,
apparent diffusivity, and estimated half life t50 reaching 50% cumulative
release.
Sample Temp. [8C] n kT 103 DeT 10
9 [mm2 minS1] t50 [h]
F68 4 0.781 0.62 0.96 41.3
25 0.77 1.22 3.63 27.5
37 0.762 2.00 8.49 16.3
45 0.588 28.15 177.12 2.1
F68-Ge 4 0.799 0.10 0.03 270.6
25 0.783 0.47 0.62 82.9
37 0.773 0.79 1.73 42.1
45 0.603 18.26 87.57 3.9
F68-EDC 4 0.808 0.07 0.02 277.8
25 0.787 0.33 0.31 83.1
37 0.776 0.59 0.91 41.5
45 0.616 14.18 60.67 6.0
F68-EDC-IO 4 0.846 0.05 0.02 416.7
25 0.84 0.24 0.25 92.3
37 0.833 0.41 0.85 41.6
45 0.615 15.71 73.02 4.8
Figure 7. Cumulative vitamin B12 release as a function of time for four F68
series nanocapsules at various temperatures from 4 to 45 8C as indicated in
the parentheses. Many low temperature data are too close to be resolved
on this graph but their relative order is the same as 45 8C. Release data
under an external magnetic field for F68-IO also shown (mag heat).
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normally achieved at 45 8C. According to Figure 6 the shrinkage is
already nearly complete at 45 8C, so magnetic heating should not
cause much more squeezing of the core. Therefore, the burst-like
accelerated release under magnetic heating cannot be attributed
to the volume change alone.
The TEMmicrograph presented in Figure 8a shows that when
nanocapsules experienced a thermal excursion to 45 8C but
without a magnetic field they remained spherical although some
(smaller spheres in Fig. 8a) had apparently shrunk indicating
drug release may have occurred. In contrast, after exposure to a
magnetic field many nanocapsules lost their spherical shape, as
shown in Figure 8b–d. Some appeared to be faceted suggesting
recrystalization (Fig. 8c); others have coarsened considerably
suggesting grain growth (Fig. 8d). Clearly, these changes are
highly disruptive which may correspond to the scenario depicted
in Figure 1b leading to a burst of drug release.
3. Discussion
3.1. Shell Thickness of Nanocapsules
Although double-layer microcapsules typically have a water-in-oil-
in-water configuration, following Choi et al.[6] we have removed
the oil layer by evaporation, so that the hydrophobic sides of the
two layers are presumably in contact. According to Figure 2, the
difference between the size of the double-emulsion nanocapsule
and the single-emulsion nanocapsule (oil-in-W2) is a constant,
about 5–7 nm in the F127 series and 10–15 nm in the F68 series.
This thickness difference may represent the thickness of a single-
layer. In an earlier report, a small-angle neutron scattering
measurement of pluronic 105 (containing (EO)37(PO)56(EO37)
blocks) gave a double-layer width of 9.5 nm, which is of the same
order of magnitude.[8]
For comparison, we next estimate the single-layer thickness
using another method. From Figure 2, we see that there is a
critical concentration of 1 g pluronic/1mL oil above which a
constant size is reached for both types (F127 and F68) of
nanocapsules. This suggests that the excess pluronic is dissolved
and not incorporated in the shell. Since the density of pluronic
and oil is similar, the above critical concentration corresponds to a
volume ratio Vpluronic/Voil about 1 for the ‘‘equilibrated’’ oil-in-
water micelles of single-shell. The single-shell thickness of such
equilibrated micelle can be estimated from the size data in
Figure 2 and the spherical geometry with a core radius r and a
shell thickness a: the shell to (oil) core volume ratio is about r/3a
and the diameter 2rþ 2a should correspond to the steady-state
size in Figure 2 (the single-emulsion nanocapsules). From this,
the single-shell thickness is estimated to be about 2.4 nm for F127
and 10.3 nm for F68, at 25 8C. These values fall in the same range
as estimated before.
3.2. Stability of Nanocapsules and Controlled Drug Release
Nanocapsules reported in this work are highly stable at room
temperature and below. This is reflected in the low release rate at
4 and 25 8C. An estimate of the half life (t50) required to reach 50%
releasemay be obtained by replotting Figure 7 in a log–log form to
extrapolate it to Mt/M1¼ 0.5 (figure not shown).[9] These half
lives are listed in Table 2, and they range from 40 to 400 h
indicating good (4 8C) storage stability. It is also clear that
crosslinking the double-layer improves the stability, as reflected in
both the half life and the apparent diffusivity De in Table 2.
According to Table 2, the exponent n decreases with increasing
temperature gradually approaching 0.5, corresponding to
diffusion-controlled release (Fickian diffusion). Taking the data
at 45 8C and assuming a diffusion mechanism, then the diffusion
distance (L) may be estimated by L¼ (2Det)1/2 with t being the
diffusion time. All the data in Figure 7 suggest that 50% release is
reached at 45 8C after about 300min. Meanwhile, the apparent
diffusivity is of the order of 107mm2min1 according to Table 2.
This leads to an estimate of L of 7.7 nm, which seems to
correspond to the single-layer thickness of F68, or the half
thickness of the double-layer micelles used in these experiments.
At lower temperature, the exponent n rises toward one. This
indicates that the diffusion of B12 across the PEO-PPO-PEO shell
is either non-Fickian or there is some binding between them at
the interface or inside the shell. Such behavior holds for all the
F68-series nanocapsules nomatter whether they are cross-linked/
IO-containing or not. This is not surprising since they all share a
very similar CMT (varying from 39.3 to 40.5 8C if we exclude
unmodified F68, which has a CMTof 43.2 8C). This relatively high
CMT is partially responsible for the excellent stability of the
nanocapsules at room temperature and below.
3.3. Magnetic Heating and Core Restructure
Under magnetic heating, burst-like release was seen which is
likely due to the irreversible and disruptive changes shown in
www.afm-journal.de
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Figure 8. Transmission electron micrographs of F68-IO nanocapsules
showing a) uneven shrinkage after heating to 45 8C; b) unevenly restruc-
tured core and shell after magnetic heating, with c) structure disruption
and faceting, and d) crystal coarsening.
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Figure 8. Such changes were clearly caused by a local temperature
increase inside the IO, which must reach several hundred
degrees of centigrade since rapid diffusion in IO is not expected
below 300 8C. This large temperature increase should not extend
much beyond the IO/water interface since according to the
standard heat conduction theory, the radial heat flux from a hot
sphere is inversely proportional to the radius and the temperature
rise is nearly completely dissipated within one radius from the
sphere. This means that the temperature rise can be sustained
only within 2–4 nm from the IO/water interface, given the initial
size of IO of 5–7 nm according to Figure 5c).
In our experiment, cooling water was supplied to maintain a
constant temperature in the water bath during magnetic heating.
Using similar experimental configurations but without active
cooling, an initial temperature rise of the water solution at a linear
rate (RW) of 0.1–1 8C s
1 has been reported.[10] Since the energy
input to heat up the water comes entirely from the heat generated
in the magnetic particles, we can calculate the heating rate RIO of
the IO nanoparticles in terms of RW using VIORIO-
CIO¼ (1VIO)RWCW. Here VIO is the volume fraction of IO
relative to the solution, and CW and CIO are volumetric speciﬁc
heat of water and IO, respectively. Our experiment and most
experiments in the literature used VIO 0.001. Meanwhile,
referring to the speciﬁc heat of Fe, O, and water, we estimate
CW/CIO 1. Therefore, the calculated RIO is from 100 to 1000 8C
s1, i.e., it takes at most a few seconds for the temperature to rise
to several hundred degrees in IO before a steady state is reached.
The steady-state temperature can be easily shown to scale as G/
ar2 by balancing the heat conduction (with a thermal
conductivity a) away from IO and the heat generation rate
(G, per unit volume) within IO, which has a radius r. Without
knowing the details of interface heat transfer at the nanoscale,
though, a more deﬁnitive determination of the steady-state
temperature is not yet possible.
Recently, TEM evidence was also reported for magnetically
induced structural changes in nanosized IO that forms a shell
around a SiO2 core.
[4] This observation is supportive of our results
indicating a thermal effect on IO restructuring. Other studies
have suggested possible changes, such as reversible pore size
enlargement, in the polymer shell due to a magnetic force
alone.[11] This is because the frequency used (300Hz) in the above
study was low enough to exert a distortion force but not high
enough to generate any significant heat. Given the high frequency
of our experiment and the rather slow Brownian relaxation of the
shell (70 nm in size),[12] we believe the magnetic force was too fast
to be followed by the IO and the nanocapsule to cause any shell
distortion. Even if the force did cause a reversible distortion and
pore enlargement, these relatively small and subtle changes are
probably insignificant compared to the massive crystal coarsen-
ing and disruption evident in Figure 8.
4. Conclusions
(i) Self-assembled aqueous nanocapsules containing a hydro-
philic core and a crosslinked yet temperature-sensitive
shell have been successfully prepared using PEO-PPO-
PEO triblock copolymers, 4-nitrophenyl chloroformate
(NPC), gelatin, and 1-ethyl-3-(3-dimethylaminopropyl) car-
bodiimide. The core may be rendered magnetic by incorpor-
ating iron oxide (IO) nanoparticles that form via internal
precipitation.
(ii) The nancapsules are spherical exhibiting a hydrophilic-to-
hydrophobic transition at a characteristic but tunable
temperature (CMT) triggering a size contraction as much
as 6.5 times. With crosslinking and IO filling the size
contraction decreases to a ratio of 2.6, allowing a large
contraction of the core volume exceeding 17 times.
(iii) The crosslinked nanocapsules with a CMT from 39 to 43 8C
exhibit very little leakage at 4 8C and 25 8Cwith an estimated
half life of 270–410 and 80–90 h, respectively, with or without
IO. Their half life at 37 8C still exceeds 40 and 41.6 h, which
decreases to about 5 h at 45 8C reflecting a diffusivity tran-
sition across the CMT.
(iv) Responding to external magnetic induction, magnetic nano-
capsules undergo irreversible structure changes including
IO crystal coarsening, core/shell disruption, and rapid
release of 80% of the core content within 5min. Such
burst-like response may be utilized for controlled drug
release as illustrated here using a model drug vitamin B12.
5. Experimental
Synthesis of Activated PEO-PPO-PEO Polymers (F127 and F68): We
used two commercial PEO-PPO-PEO thermal-sensitive polymers, pluronic
F127 and F68, (Sigma, USA) to form two series of core/shell nanocapsules
in this study. F127 has a (EO)100(PO)65(EO)100 block structure with an EO/
PO ratio of 3.08, and F68 has a (EO)76(PO)29(EO)76 block structure with an
EO/PO ratio of 5.24. The polymer (20 g of F127 or F68) was first dissolved
in 60mL of methylene chloride (Fisher Scientific, USA). In a dropwise
manner this solution was added to a stirred solution of methylene chloride
(60mL) containing NPC (2 g). The activation reaction of forming covalent
bonds between NPC and pluronics proceeded with gentle stirring (5 h) at
room temperature under a nitrogen atmosphere. The activated polymer
(F127-NPC or F68-NPC) was precipitated, washed five times in ice-cold
diethyl ether, and dried under vacuum. To determine the activation density,
a known amount of F127-NPC or F68-NPCwas treated with NaOH (0.2N)
at 25 8C (2 h). The concentration of NPC released in the aqueous phase was
quantified spectrophotometrically at 410 nm.
Fabrication of Activated PEO-PPO-PEO Nanocapsules: Single-layer
nanocapsules containing one layer of activated PEO-PPO-PEO were
synthesized using a single-emulsification (SE)/solvent-evaporation
method. An oil phase (methylene chloride solution, 1mL) containing
various amount of F127-NPC or F68-NPC (0.05–1.5 g) was added dropwise
to a water phase (10mL) (W2, PBS) at pH 7.4. The mixture was sonicated
(10min) using an ultrasonic homogenizer (Virsonic, VirTis, USA)
operating at 20 kHz to obtain oil-in-water micelles, F127-SE or F68-SE,
as shown in Figure 1a.
Double-layer nanocapsules containing two layers of PEO-PPO-PEO
were synthesized using a double-emulsification (DE)/solvent-evaporation
method. The first water phase W1 (PBS, 0.1mL) was added dropwise to an
oil phase (methylene chloride solution, 1 ml) containing various amount of
F127-NPC or F68-NPC (0.05–1.5 g). The mixture was sonicated (10min) to
obtain water (W1)-in-oil micelles. Next, the micelle solution was added
dropwise to a second water phase W2 (PBS, 10mL). The mixture was again
sonicated (10min) to obtain W1-in-oil-in-W2 micelles. The sample was
called F127-DE or F68-DE (or F127-NPC-DE and F68-NPC-DE to
emphasize that the outer shell is NPC-activated.) These emulsion
solutions were next dialyzed (dialysis membrane with an Mw cutoff of
14 000) and the product stored at 4 8C until further use. The oil phase
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(methylene chloride) can be removed by evaporation at 30 8C to leave a
double-layer micelle containing a W1 core, yet itself suspended in the W2
phase.
Fabrication of Double-Layer Cross-linked Nanocapsules: A schematic of
the nanocapsules with a cross-linked shell is depicted in Figure 1a.
Essentially, the F127-DE or F68-DE activated with NPC is cross-linked with
gelatin (Sigma), a hydrolyzed natural protein polymer rich in amino and
carboxyl groups. To introduce gelatin to these double-layer micelles, we
modified the second step in their preparation and added gelatin of various
amount (1–10mgmL1) to the W2 phase (PBS) prior to the addition of the
W1-in-oil micelles. The emulsion of the resultant W1-in-oil-in-W2 micelles
was immediately transferred to a water bath at 4 8C and held for 24 h to
crosslink gelatin. After that, the emulsion solution was stirred at 30 8C to
remove residual methylene chloride until the solution became clear. In
addition, the gelatin can be fully cross-linked with the (dropwise) addition
of 1ml of 0.1 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC,
Sigma) to the above solution, held at 4 8C (24 h) [13,14]. These emulsion
solutions were also dialyzed and the product stored at 4 8C until further use.
The product after the first-step cross-linking will be referred to as F127-Ge
or F68-Ge, and the product after the second-step cross-linking will be
referred to as F127-EDC or F68-EDC.
Encapsulation of Drug and Iron Oxide into Nanocapsules: The above
procedure was modified to incorporate a model drug vitamin B12 (Sigma),
a cobalamin, into the W1 phase; then this phase was used to prepare the
double-layer nanocapsules as before followed by cross-linking. The
concentration used was 10mg mL1 vitamin B12 in 0.1mL PBS. To
incorporate iron oxide, we used in situ co-precipitation of Fe(II) and Fe(III)
salts. Briefly, FeCl3  6H2O (Riedel-deHae¨n) (0.1mL of 1.08 g mL1) and
FeCl2  4H2O (Fluka) (0.4 gmL1), together with vitamin B12 (10mgmL1)
were mixed into PBS to form the W1 phase; then this phase was used to
prepare the double-layer nanocapsules as before. After the final cross-
linking steps, the pH of the mixture solution was adjusted to 10 by adding
ammonia solution (33%) under stirring, followed by heat treatment at
60 8C for 30min to precipitate iron oxide particles, as shown in Figure 1b.
This product will be referred to as F68-IO. Other washing and storage
procedures are the same as before.
Drug Release Test: In vitro drug release from the W1 core of various
double-layer nanocapsules was evaluated by incubating the vitamin B12-
containing nanocapsules in 20mL of PBS at various temperatures. At
specific time intervals, some PBS solution was withdrawn and its
concentration of vitamin B12 was measured by UV spectrum (361 nm).
The percentage cumulative release was determined from this concentra-
tion after normalizing it by the amount of the initially loaded vitamin B12.
The data were analyzed in terms of various kinetic mechanisms by fitting it
to the time law of the form [15,16].
Mt
M1
¼ ktn (2)
whereMt is the cumulative release after time t,M1 the cumulative release
at time infinity, and k and n are fitting coefficients.
We attempted to increase the release rate by radio frequency magnetic
heating generated by an induction heater (15 kW) operating at 50–
100 kHz.[17,18] The configuration is similar to the one reported in the
literature [5,10], with an induction (copper) coil of eight loops delivering a
magnetic field (2.5 kA m1). The solution was kept at 15 8C through a water
bath during the experiment. The amount of the PBS solution used was
10mL containing 0.2 g nanocapsules. Other procedures were the same as
described before.
Characterization of Size and Microstructure: The chemical structure of
the activated polymers was characterized by proton nuclear magnetic
resonance spectroscopy (1H-NMR) to confirm the sites and degrees of
substitution. The samples were dissolved in CDCl3 and the spectra were
recorded by an NMR spectrometer (Bruker Avance-500, operating at
500MHz) equipped with a microprocessor-controlled gradient unit and an
inverse-detection multinuclear BBI probe with an actively shielded z-
gradient coil. For nanocapsule characterization, dynamic light scattering
(DLS, zetasizer-3000HS,Malvern, UK) was used for size determination and
microscopy was performed using a transmission electron microscope
(TEM, JEM-2010, JEOL, Japan) operating at 200 kV.
Acknowledgements
This work was supported by the National Science Council of the Republic of
China, Taiwan under contract nos. NSC96-2627-B-009-006 and NSC96-
2113-M009-027-MY2, and by the US National Science Foundation under
grant no. DMR- 05-20020 (MRSEC). Supporting Information is available
online from Wiley InterScience or from the author.
Received: September 3, 2008
Revised: November 3, 2008
Published online:
[1] J. Kost, R. Noecker, E. Kunica, R. Langer, J. Biomed. Mater. Res. 1985, 19,
935.
[2] J. Kost, J. Wolfrum, E. Kunica, R. Langer, J. Biomed. Mater. Res. 1987, 21,
1367.
[3] V. M. De Paoli, S. H. De Paoli Lacerda, L. Spinu, B. Ingber, Z. Rosenzweig,
N. Rosenzweig, Langmuir 2006, 22, 5894.
[4] S. H. Hu, S. Y. Chen, D. M. Liu, C. S. Hsiao, Adv. Mater. 2008, 20, 2690.
[5] A. M. Derfus, G. V. Maltzahn, T. J. Harris, T. Duza, K. S. Vecchio, E.
Ruoslahti, S. N. Bhatia, Adv. Mater. 2007, 19, 3932.
[6] S. H. Choi, J. H. Lee, S. M. Choi, T. G. Park, Langmuir 2006, 22, 1758.
[7] J. B. Leach, C. E. Schmidt, Biomaterials 2005, 26, 125. &References have
been renumbered. Please check.&.
[8] L. Guo, R. H. Colby, J. Rheol. 2001, 45, 1223.
[9] S. M. Ansell, S. A. Johnstone, P. G. Tardi, L. Lo, S. Xie, Y. Shu, T. O.
Harasym, N. L. Harasym, L. Williams, D. Bermudes, B. D. Liboiron, W.
Saad, R. K. Prud’homme, L. D. Mayer, J. Med. Chem. 2008, 51, 3288.
[10] D. H. Kim, D. E. Nikles, D. T. Johnson, C. S. Brazel, J. Magn. Magn. Mater.
2008, 320, 2390.
[11] Z. M. Lu, D. Prouty, Z. Guo, V. O. Golub, C. S. S. R. Kumar, Y. M. Lvov,
Langmuir 2005, 21, 2042.
[12] R. E. Rosensweig, J. Magn. Magn. Mater. 2002, 252, 370.
[13] W. C. Lin, T. Y. Liu, M. C. Yang, Biomaterials 2004, 25, 1947.
[14] T. Y. Liu, W. C. Lin, L. Y. Huang, S. Y. Chen, M. C. Yang, Biomaterials 2005,
25, 1437.
[15] P. L. Ritger, N. A. Peppas, J. Controlled Release 1987, 5, 37.
[16] J. S. Ahn, H. K. Choi, M. K. Chun, J. M. Ryu, J. H. Jung, Y. U. Kim, C. S. Cho,
Biomaterials 2002, 23, 1411.
[17] S. H. Hu, T. Y. Liu, D. M. Liu, S. Y. Chen, Macromolecules 2007, 40, 6786.
[18] S. H. Hu, T. Y. Liu, H. Y. Huang, D. M. Liu, S. Y. Chen, Langmuir 2008, 24,
239.
Q1: Author: Please clarify throughout the article all editorial/
technical requests marked by black boxes.
*: Author: Please note that Figure of Toc will be printed in
colour.
www.afm-journal.de
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
467
48
49
50
51
52
53
54
55
56
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
8  2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Adv. Funct. Mater. 2008, 18, 1–8
